Control of Innate Immunity, Collaborative Innovation Partnership, Kagawa, Japan.
Macrophi Inc., Kagawa, Japan.
In Vivo. 2024 Sep-Oct;38(5):2190-2196. doi: 10.21873/invivo.13682.
BACKGROUND/AIM: In a previous report, our group showed that oral administration of lipopolysaccharides (LPS) from Pantoea agglomerans can prevent the progression of streptozotocin (STZ)-induced diabetes-related cognitive dysfunction (DRCD) in mice without causing significant side-effects. However, the treatment effects of oral administration of LPS to DRCD remain unknown.
We modified our previous animal experimental model to investigate whether oral administration of LPS can recover cognitive function after DRCD onset.
The Morris water maze (MWM) revealed a significant decrease in learning and memory abilities at 13 days after intracerebroventricular administration of STZ, thereby providing evidence of the occurrence of DRCD in the animal model. Oral administration of LPS (1 mg/kg per day) started after cognitive impairment was observed. After 28 days of treatment, mice receiving LPS via the oral route showed significant recovery of spatial learning ability, a symptom of early dementia, while only a trend toward recovery was seen for spatial memory compared to the untreated group.
These results, limited to MWM, suggest that oral administration of LPS is a promising therapeutic strategy for restoring decreased spatial learning ability.
背景/目的：在之前的一份报告中，我们的团队表明，口服聚集泛菌脂多糖（LPS）可以预防链脲佐菌素（STZ）诱导的糖尿病相关认知功能障碍（DRCD）在小鼠中进展，而不会引起明显的副作用。然而，口服 LPS 对 DRCD 的治疗效果仍不清楚。
我们修改了之前的动物实验模型，以研究口服 LPS 是否可以在 DRCD 发病后恢复认知功能。
Morris 水迷宫（MWM）显示，在侧脑室注射 STZ 后 13 天，学习和记忆能力明显下降，从而为动物模型中发生 DRCD 提供了证据。在观察到认知障碍后开始口服 LPS（每天 1 毫克/千克）。经过 28 天的治疗，通过口服途径接受 LPS 的小鼠表现出空间学习能力的显著恢复，这是早期痴呆的症状，而与未治疗组相比，仅显示出空间记忆恢复的趋势。
这些仅限于 MWM 的结果表明，口服 LPS 是恢复空间学习能力下降的一种有前途的治疗策略。
